GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » EV-to-EBIT

VolitionRX (VolitionRX) EV-to-EBIT : -1.64 (As of Apr. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is VolitionRX EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, VolitionRX's Enterprise Value is $58.18 Mil. VolitionRX's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.46 Mil. Therefore, VolitionRX's EV-to-EBIT for today is -1.64.

The historical rank and industry rank for VolitionRX's EV-to-EBIT or its related term are showing as below:

VNRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.87   Med: -5.82   Max: -0.91
Current: -1.64

During the past 13 years, the highest EV-to-EBIT of VolitionRX was -0.91. The lowest was -14.87. And the median was -5.82.

VNRX's EV-to-EBIT is ranked worse than
100% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.23 vs VNRX: -1.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. VolitionRX's Enterprise Value for the quarter that ended in Dec. 2023 was $42.94 Mil. VolitionRX's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.46 Mil. VolitionRX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -82.57%.


VolitionRX EV-to-EBIT Historical Data

The historical data trend for VolitionRX's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VolitionRX EV-to-EBIT Chart

VolitionRX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.39 -8.59 -5.67 -4.41 -1.21

VolitionRX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.41 -3.63 -2.78 -1.37 -1.21

Competitive Comparison of VolitionRX's EV-to-EBIT

For the Diagnostics & Research subindustry, VolitionRX's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VolitionRX's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, VolitionRX's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where VolitionRX's EV-to-EBIT falls into.



VolitionRX EV-to-EBIT Calculation

VolitionRX's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=58.181/-35.456
=-1.64

VolitionRX's current Enterprise Value is $58.18 Mil.
VolitionRX's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VolitionRX  (AMEX:VNRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

VolitionRX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-35.456/42.9390811
=-82.57 %

VolitionRX's Enterprise Value for the quarter that ended in Dec. 2023 was $42.94 Mil.
VolitionRX's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VolitionRX EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of VolitionRX's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


VolitionRX (VolitionRX) Business Description

Traded in Other Exchanges
N/A
Address
1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Executives
Eight Corp Ltd 10 percent owner C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert director, officer: SECRETARY 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds director, officer: PRESIDENT AND CEO 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Guy Archibald Innes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall director 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef officer: Chief Scientific Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Michel Gaetan other: Manager Belgian Volition SPRL 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway other: CEO-Singapore Volition 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer officer: GC - Volition Diagnostics 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor officer: Group Chief Marketing Officer 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md officer: Chief Medical Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014